ESMO 2026 | Dr. Changhoon Yoo: Precision Treatment Insights From the OPTIMUM Study in DDR-Mutated Biliary Tract Cancer

ESMO 2026 | Dr. Changhoon Yoo: Precision Treatment Insights From the OPTIMUM Study in DDR-Mutated Biliary Tract Cancer

Biliary tract cancer is highly aggressive and has limited treatment options. Mutations in DNA damage repair (DDR)-related genes offer a new direction for precision treatment of advanced biliary tract cancer. At the 2026 European Society for Medical Oncology (ESMO) Congress, Dr. Changhoon Yoo from Asan Medical Center, South Korea, presented the results of the randomized Phase II OPTIMUM study (Abstract No. LBA22) in an oral presentation. The study explored the value of maintenance therapy with olaparib, with or without durvalumab, following platinum-based chemotherapy in patients with advanced biliary tract cancer harboring DDR gene mutations.
Professor Lorenza Rimassa: Seven-Year HIMALAYA Follow-Up—Insights Into Long-Term Survival in Advanced HCC and Implications for Clinical Practice

Professor Lorenza Rimassa: Seven-Year HIMALAYA Follow-Up—Insights Into Long-Term Survival in Advanced HCC and Implications for Clinical Practice

The 2026 European Society for Medical Oncology (ESMO) Congress was held in Spain, bringing together leading oncology experts and researchers from around the world to share major updates in hepatobiliary oncology and offer new perspectives on the clinical management of hepatocellular carcinoma (HCC). The HIMALAYA study established the important role of the STRIDE regimen in the first-line treatment of advanced HCC. At this year's congress, Professor Lorenza Rimassa of Humanitas University and Humanitas Research Hospital, Italy, presented seven-year long-term overall survival data from the study, further advancing our understanding of long-term survival in advanced liver cancer. Oncology Frontier invited Professor Rimassa for an in-depth interview to discuss these important new findings, the value of tumor response measures in predicting long-term survival, and the implications of the STRIDE regimen for clinical decision-making. She also shared insights into other promising developments presented at the congress, bringing the latest international perspectives to clinicians in China.
ESMO LBA Insights | Professor Chenlei Wen: HRS-4642 and the Move Toward Perioperative KRAS-Targeted Therapy in Pancreatic Cancer

ESMO LBA Insights | Professor Chenlei Wen: HRS-4642 and the Move Toward Perioperative KRAS-Targeted Therapy in Pancreatic Cancer

The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27, local time. As one of the most influential comprehensive academic events in global oncology, the ESMO Congress brings together leading international experts, clinical researchers, and pharmaceutical innovators to showcase cutting-edge advances in cancer diagnosis and treatment.
International Experts Discuss OptiTROP-Lung06: ADC Plus Immunotherapy Challenges the First-Line Standard in PD-L1-Negative NSCLC

International Experts Discuss OptiTROP-Lung06: ADC Plus Immunotherapy Challenges the First-Line Standard in PD-L1-Negative NSCLC

The 2026 Congress of the European Society for Medical Oncology (ESMO) was held in Madrid, Spain, from October 23 to 27. At this premier global oncology event, the OptiTROP-Lung06 study, led by Professor Caicun Zhou of Shanghai East Hospital, presented its findings in a major oral presentation, with simultaneous publication in the New England Journal of Medicine (NEJM). This Phase III study provided the first head-to-head evidence that the TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) plus pembrolizumab was superior to the standard regimen of platinum-based doublet chemotherapy plus pembrolizumab as first-line treatment for patients with driver gene-negative, PD-L1-negative (expression <1%) nonsquamous non-small cell lung cancer (NSCLC).
ESMO Voices from China | Professor Shaodong Hong: TROP2 ADC Plus Immunotherapy in First-Line NSCLC — Encouraging Efficacy with BAT8008-Based Combination Therapy

ESMO Voices from China | Professor Shaodong Hong: TROP2 ADC Plus Immunotherapy in First-Line NSCLC — Encouraging Efficacy with BAT8008-Based Combination Therapy

For patients with advanced driver gene-negative non-small cell lung cancer (NSCLC), current first-line standard treatment primarily relies on immunotherapy alone or immunotherapy combined with chemotherapy. However, long-term patient outcomes still need to be further improved. Antibody-drug conjugates (ADCs) targeting trophoblast cell-surface antigen 2 (TROP2), through their dual mechanisms of cytotoxicity and immune activation, may enhance the effects of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade.
ESMO Insights from China | Professor Xiaohua Wu: Four Chinese-Originated Studies Reshape the Treatment Landscape in Gynecologic Oncology

ESMO Insights from China | Professor Xiaohua Wu: Four Chinese-Originated Studies Reshape the Treatment Landscape in Gynecologic Oncology

The 2026 Congress of the European Society for Medical Oncology (ESMO 2026) was held in Madrid, Spain, from October 23 to 27. At this year's congress, the team led by Professor Xiaohua Wu from Fudan University Shanghai Cancer Center presented four studies of innovative drugs developed in China, spanning three major gynecologic malignancies: cervical cancer, ovarian cancer, and endometrial cancer.